FOURIER (TIMI 59) was a double-blind, randomized, placebo-controlled, multicenter study assessing the Impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease.  EBBINGHAUS was a cognitive study of patients enrolled in the FOURIER trial. MAIN RESULTS:Evolocumab and Clinical Outcomes in Patients … Continue reading FOURIER (TIMI 59) / EBBINGHAUS